Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, July 8th, Helen Torley sold 1,923 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $79.77, for a total value of $153,397.71.
• On Wednesday, June 3rd, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $69.07, for a total value of $690,700.00.
• On Monday, June 1st, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00.

Halozyme Therapeutics Trading Down 1.4%

Shares of Halozyme Therapeutics stock opened at $106.12 on Friday. Halozyme Therapeutics, Inc. has a 1 year low of $61.22 and a 1 year high of $107.96. The company’s fifty day simple moving average is $82.42 and its 200-day simple moving average is $73.50. The company has a market cap of $12.04 billion, a price-to-earnings ratio of 31.68, a PEG ratio of 0.43 and a beta of 0.85. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on HALO. Wells Fargo & Company boosted their price target on Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Finally, Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. MidFirst Bank bought a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth about $27,000. Larson Financial Group LLC increased its position in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $28,000. Measured Wealth Private Client Group LLC lifted its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Halozyme Therapeutics in the second quarter valued at about $30,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.